WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 576084

CAS#: 503068-34-6 (free base)

Description: Vilanterol, also known as GW-642444, is a long-acting beta-2 agonist. It selectively induces cAMP accumulation in CHO cells expressing the β2-AR over the β1- and β3-ARs (EC50s = 0.4, 398, and 794 nM for the human receptors, respectively). Vilanterol inhibits contractions induced by electrical stimulation in isolated superfused guinea pig trachea strips. It inhibits bronchospasms induced by histamine. Formulations containing vilanterol, in combination with fluticasone, have been used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Chemical Structure

CAS# 503068-34-6 (free base)

Theoretical Analysis

MedKoo Cat#: 576084
Name: Vilanterol
CAS#: 503068-34-6 (free base)
Chemical Formula: C24H33Cl2NO5
Exact Mass: 485.17
Molecular Weight: 486.430
Elemental Analysis: C, 59.26; H, 6.84; Cl, 14.58; N, 2.88; O, 16.45

Price and Availability

Size Price Availability Quantity
1mg USD 350 2 Weeks
5mg USD 950 2 Weeks
Bulk inquiry

Related CAS #: 503070-58-4 (trifenatate)   503068-34-6 (free base)    

Synonym: GW 642444; GW642444; GW-642444; Vilanterol

IUPAC/Chemical Name: (R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol


InChi Code: InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1


Appearance: A solution in ethanol

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, DMF, Ethanol

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Soluble in DMSO 0.0 100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 486.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1. Cazzola, M., Calzetta, L., and Matera, M.G. β2-adrenoceptor agonists: Current and future direction. Br. J. Pharmacol. 163(1), 4-17 (2011).

2. Mach, R.H., Nader, M.A., Ehrenkaufer, R.L., et al. Comparison of two fluorine-18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: In vitro binding studies and positron emission tomography. Synapse 24(4), 322-333 (1996).

3. Procopiou, P.A., Barrett, V.J., Bevan, N.J., et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: An antedrug approach. J. Med. Chem. 53(11), 4522-4530 (2010).

4. De Coster, D.A., and Jones, M. Tailoring of corticosteroids in COPD management. Curr.Respir.Care Rep. 3, 121-132 (2014).

5. Cohen, J.S., Miles, M.C., Donohue, J.F., et al. Dual therapy strategies for COPD: The scientific rationale for LAMA + LABA. Int. J. Chron. Obstruct. Pulmon. Dis. 11, 785-797 (2016).